7,8-Dihydroxyflavone vs NSI-189

7,8-Dihydroxyflavone wins for acute impact on mood, focus, and synaptic plasticity, rapid onset (hours to days), low cost, and ease of sourcing. Tolerability is high, but short half-life and hepatic metabolism caveats apply.

NSI-189 wins for sustained hippocampal neurogenesis, durable cognitive and mood improvements that persist post-cycle, and solid safety/tolerability in clinical trials. The effect is slower (weeks), cost and sourcing are bigger hurdles, and full human data is still sparse outside of depression trials.

Pick 7,8-Dihydroxyflavone if:

• A fast-acting focus or mood nootropic is needed
• The goal is neuroprotection alongside harsher compounds or cycles
• Acute memory/learning enhancements (short-term use)
• Lower budget or off-the-shelf sourcing is preferred
• The protocol allows for sublingual or daily-multidose regimens

Pick NSI-189 if:

• Long-term hippocampal neurogenesis is the goal (structural brain change)
• Cognitive/emotional recovery from SSRI, TBI, stress, etc.
• Seeking durable effects that persist after the cycle
• Cost and sourcing are less of a concern than efficacy stack
• Willingness to wait 2–4 weeks for primary effects